Study for patients with advanced triple negative breast cancer

Phase 2 (Expansion Cohort): To perform an evaluation of the efficacy of entinostat at the RP2D in combination with atezolizumab in patients with aTNBC, as determined by the duration of progression-free survival.

August 09, 2017